Stock AnalizAcadia Pharmaceuticals Inc. ACAD
Biotechnology: Pharmaceutical Preparations · IPO 1985 · data as of November 13, 2026
Acadia Pharmaceuticals Inc. (ACAD) is a healthcare company listed in the US with a market value of about $3.2B. In the twelve months to September 30, 2026 it had revenue of $1.2B and net income of $362M, a net margin of 30.1%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is financial health (5/5); the weakest is shareholder returns (1/5).
Key numbers: a P/E of 8.8, a price to free cash flow of 39.5, 5-year revenue growth of 19% a year, a 5-year average ROIC of -8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 36% below the current price.
Score: 2.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Pays a dividend
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.1B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M |
| Net income | $362M | $391M | $226M | -$61M | -$216M | -$168M | -$282M | -$235M | -$245M | -$289M | -$271M |
| Free cash flow | $82M | $105M | $157M | $17M | -$114M | -$127M | -$144M | -$152M | -$170M | -$219M | -$210M |
| EPS (diluted) | $2.12 | $2.30 | $1.36 | $-0.37 | $-1.34 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| Net margin | 30.1% | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% |
| ROIC | — | 6.5% | 25.8% | -11.9% | -38.2% | -22.2% | -33.5% | -27.5% | -40.8% | -68.9% | -41.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 19 analysts is $30.53, 63% above the current price; targets range from $16.00 to $38.00; the consensus rating is “Buy”; expected EPS is $0.75 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Acadia Pharmaceuticals’s P/E ratio?
About 8.8, based on the last twelve months of diluted earnings per share (forward P/E about 18.5).
Is Acadia Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 36% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Acadia Pharmaceuticals pay a dividend?
Not currently.
Is Acadia Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Acadia Pharmaceuticals scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.